TITLE: “Discovering biomarkers for predicting response to neo-adjuvant ADT and radionuclide treatment in high-risk prostate cancer”
ABSTRACT: Prostate cancer is the number one cause of cancer death in non-smoking American men. Next generation treatments for prostate cancer include androgen deprivation therapy (ADT) drugs such as Enzalutamide and radionuclide treatments like Lu-PSMA-617. While both of these treatment approaches are initially effective, prostate cancer almost always recurs. We use multimodal genomic data to discover clinically useful prostate cancer subtypes to determine mechanisms of treatment resistance. We further explore how these subtypes relate to the dearth of model systems in prostate cancer research – and whether we are ignoring clinically relevant genetic diversity in our drug development pipeline.
